MCID: HPT021
MIFTS: 74

Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis

MalaCards integrated aliases for Hepatitis:

Name: Hepatitis 39 12 77 30 56 6 44 45 15 74
Chronic Persistent Hepatitis 12 56 74
Chronic Hepatitis 12 15 17
Acute Hepatitis 12 30 74
Hepatitis, Chronic 45 74
Acute and Subacute Liver Necrosis 12
Acute/subac. Necrosis of Liver 12
Hepatitis Chronic 56
Hepatitis, Animal 74
Animal Hepatitis 12
Hepatitis a 74

Classifications:



Summaries for Hepatitis

MedlinePlus : 44 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver. Viruses cause most cases of hepatitis. The type of hepatitis is named for the virus that causes it; for example, hepatitis A, hepatitis B or hepatitis C. Drug or alcohol use can also cause hepatitis. In other cases, your body mistakenly attacks healthy cells in the liver. Some people who have hepatitis have no symptoms. Others may have Loss of appetite Nausea and vomiting Diarrhea Dark-colored urine and pale bowel movements Stomach pain Jaundice, yellowing of skin and eyes Some forms of hepatitis are mild, and others can be serious. Some can lead to scarring, called cirrhosis, or to liver cancer. Sometimes hepatitis goes away by itself. If it does not, it can be treated with drugs. Sometimes hepatitis lasts a lifetime. Vaccines can help prevent some viral forms.

MalaCards based summary : Hepatitis, also known as chronic persistent hepatitis, is related to hepatitis d and hepatitis a, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatitis is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Jak-Stat Signaling Pathway (sino) and Vitamin digestion and absorption. The drugs Guaifenesin and Methadone have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and t cells, and related phenotype is mortality/aging.

Wikipedia : 77 Hepatitis is inflammation of the liver tissue. Some people have no symptoms whereas others develop... more...

Related Diseases for Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2266)
# Related Disease Score Top Affiliating Genes
1 hepatitis d 34.5 GPT IFNA2
2 hepatitis a 33.9 AFP GPT HAVCR1 HAVCR2 SEPSECS
3 autoimmune hepatitis 33.9 GPT KRT8 SEPSECS
4 viral hepatitis 33.7 AFP GPT IFNA1 IFNA2 KRT18 SEPSECS
5 hepatitis c 33.6 CLDN1 GPT IFNA1 IFNA2 IFNAR2 IFNL4
6 hepatitis b 33.6 AFP ASGR2 GPT IFNA1 IFNA2 IFNAR2
7 hepatitis c virus 33.5 CLDN1 GPT HAVCR2 IFNL4 KRT18 KRT8
8 liver disease 32.8 AFP GPT IFNA1 KRT18 KRT8 SEPSECS
9 liver cirrhosis 32.4 AFP GPT IFNA1 KRT18 KRT8
10 cryoglobulinemia, familial mixed 31.4 IFNA1 IFNA2
11 nonalcoholic steatohepatitis 31.1 GPT KRT18
12 cryptogenic cirrhosis 30.3 KRT18 KRT8
13 opisthorchiasis 30.2 AFP GPT
14 transitional cell carcinoma 29.6 IFNA2 KRT18 KRT8
15 bile duct disease 29.5 AFP GPT SLC10A1
16 viral infectious disease 29.5 GPT IFNA1 IFNA2
17 discoid lupus erythematosus 29.3 IFNA1 IFNA2
18 lymphoepithelioma-like carcinoma 29.0 KRT18 KRT8
19 hepatic veno-occlusive disease 12.6
20 hepatic venoocclusive disease with immunodeficiency 12.5
21 alcoholic hepatitis 12.5
22 hepatic encephalopathy 12.5
23 hepatic lipase deficiency 12.5
24 hepatitis e 12.5
25 congenital hepatic fibrosis 12.4
26 hepatic adenomas, familial 12.4
27 non-a-e hepatitis 12.3
28 renal-hepatic-pancreatic dysplasia 12.3
29 drug-induced hepatitis 12.3
30 porphyria, acute hepatic 12.3
31 renal-hepatic-pancreatic dysplasia 1 12.3
32 epstein-barr virus hepatitis 12.3
33 hepatic coma 12.2
34 renal-hepatic-pancreatic dysplasia 2 12.2
35 hepatic fibrosis, severe due to schistosoma mansoni infection 12.2
36 granulomatous hepatitis 12.2
37 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 12.2
38 hepatic flexure cancer 12.2
39 hepatic tuberculosis 12.2
40 fulminant viral hepatitis 12.1
41 hepatic infarction 12.1
42 acute liver failure 12.1
43 halothane hepatitis 12.1
44 hepatic angiomyolipoma 12.1
45 hepatitis b vaccine, response to 12.1
46 sclerosing hepatic carcinoma 12.0
47 hepatic vascular disease 12.0
48 hepatocellular carcinoma 12.0
49 coach syndrome 12.0
50 primary hepatic neuroendocrine carcinoma 12.0

Comorbidity relations with Hepatitis via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Cholangitis Chronic Myocardial Ischemia
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Hypothyroidism
Ischemic Heart Disease Mitral Valve Disease
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatitis:



Diseases related to Hepatitis

Symptoms & Phenotypes for Hepatitis

UMLS symptoms related to Hepatitis:


nausea and vomiting, constipation, fever, abdominal pain, pruritus, diarrhea, hepatosplenomegaly, lameness, animal, icterus, dyspepsia, heartburn, gastrointestinal gas, hepatocellular jaundice

MGI Mouse Phenotypes related to Hepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.4 AFP ASGR2 CLDN1 HAVCR2 IFNAR2 KRT18

Drugs & Therapeutics for Hepatitis

Drugs for Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 905)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
2
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
6
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
7
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
8
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99210-65-8, 215647-85-1
9
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
10
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 21645-51-2
11
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
12
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
13
Rifampicin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5381226 5458213
14
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
15
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
16
Atorvastatin Approved Phase 4,Phase 3,Phase 2 134523-00-5 60823
17
Tocopherol Approved, Investigational Phase 4,Phase 3,Not Applicable 1406-66-2 14986
18
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
19
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
20
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
21
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
22
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
23
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 111025-46-8 4829
24
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
25
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 155213-67-5 392622
26
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2921-57-5
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 302-25-0
28
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-24-8 5755
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 83-43-2 6741
30
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
31
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
32
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
33
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 174722-31-7 10201696
34
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1256388-51-8 67505836
35
Sofosbuvir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1190307-88-0 45375808
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
37 Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 8008-53-5
38
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1401-55-4
39
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
40
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
41
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154598-52-4 64139
42
Chlorhexidine Approved, Vet_approved Phase 4,Not Applicable 55-56-1 2713 9552079
43
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128-13-2 31401
44
Alprostadil Approved, Investigational Phase 4,Phase 2 745-65-3 149351 5280723
45
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123774-72-1, 83869-56-1
46
glycyrrhizin Approved, Experimental Phase 4,Phase 3,Phase 2 1405-86-3 3495
47
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48
Simvastatin Approved Phase 4,Phase 2,Phase 3,Phase 1 79902-63-9 54454
49
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 32051
50
Insulin glulisine Approved Phase 4 207748-29-6

Interventional clinical trials:

(show top 50) (show all 4693)
# Name Status NCT ID Phase Drugs
1 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
2 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
3 Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients Unknown status NCT02963714 Phase 4
4 Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients Unknown status NCT02991599 Phase 4
5 Immunogenicity of Hepatitis B Vaccination Among Drug Users Unknown status NCT02959775 Phase 4
6 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
7 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
8 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
9 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
10 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
11 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
12 Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation Unknown status NCT02417207 Phase 4 Entecavir combined long-term low-dose HBIG group intramuscular;Entecavir combined HBIG group short-term high-dose intravenous
13 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4 Entecavir;Entecavir, Adefovir;Entecavir, Adefovir
14 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
15 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
16 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
17 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4 isoniazid, rifampin, pyrazinamide
18 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
19 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
20 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
21 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
22 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
23 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
24 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4 Pegasys plus Entecavir;Entecavir
25 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
26 Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC) Unknown status NCT02745132 Phase 4
27 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
28 Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
29 Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B Unknown status NCT02532413 Phase 4 Poly IC;Entecavir
30 Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues Unknown status NCT02362490 Phase 4 peginterferon alpha 2a
31 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4 Switching from adefovir (10mg/day) to tenofovir (300mg/day)
32 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
33 The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection Unknown status NCT02412319 Phase 4 Anti-HBV placenta transfer factor injection
34 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4 telbivudine plus adefovir;lamivudine plus adefovir
35 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4 Reiferon retard
36 Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
37 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
38 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
39 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
40 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
41 Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
42 Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults Unknown status NCT02822547 Phase 4 Peginterferon alfa-2a
43 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
44 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4 LAMIVUDINE
45 Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B Unknown status NCT02482272 Phase 4 Lamivudine;Adefovir;Entecavir
46 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4 Lamivudine
47 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
48 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4 Adefovir Dipivoxil and polyene phosphatidylcholine;Adefovir Dipivoxil
49 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
50 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4 Pioglitazone;Acarbose;Metformin

Search NIH Clinical Center for Hepatitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatitis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatitis:
Promethera� HepaStem, human adult liver progenitor cells for liver diseases
Embryonic/Adult Cultured Cells Related to Hepatitis:
Adult liver progenitor cells PMIDs: 22525602 23211283 19091822 24142276 22900053

Cochrane evidence based reviews: hepatitis

Genetic Tests for Hepatitis

Genetic tests related to Hepatitis:

# Genetic test Affiliating Genes
1 Acute Hepatitis 30
2 Hepatitis 30

Anatomical Context for Hepatitis

MalaCards organs/tissues related to Hepatitis:

42
Liver, Testes, T Cells, Kidney, B Cells, Bone, Thyroid

Publications for Hepatitis

Articles related to Hepatitis:

(show top 50) (show all 40838)
# Title Authors Year
1
Extra-abdominal involvement is associated with antitubercular therapy-related hepatitis in patients treated for abdominal tuberculosis. ( 30915408 )
2019
2
Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients. ( 30315682 )
2019
3
Corticosteroid Therapy for Indeterminate Pediatric Acute Liver Failure and Aplastic Anemia with Acute Hepatitis. ( 30770193 )
2019
4
Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. ( 30827414 )
2019
5
Successful Treatment of a South African Pediatric Case of Acute Liver Failure Caused by Perinatal Transmission of Hepatitis B. ( 29601455 )
2019
6
Urinary acrolein metabolite levels in severe acute alcoholic hepatitis patients. ( 30234998 )
2019
7
Acute Alcoholic Hepatitis. ( 30454835 )
2019
8
Treatment retention in a specialized alcohol programme after an episode of alcoholic hepatitis: Impact on alcohol relapse. ( 30654998 )
2019
9
Current trials and novel therapeutic targets for alcoholic hepatitis. ( 30658731 )
2019
10
Endpoints and patient stratification in clinical trials for alcoholic hepatitis. ( 30658732 )
2019
11
Liver transplantation for alcoholic hepatitis. ( 30658734 )
2019
12
Efficacy of g-csf in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. ( 30664267 )
2019
13
Non-uremic calciphylaxis associated with alcoholic hepatitis: A case report. ( 30705725 )
2019
14
Porphyromonas gingivalis as a Possible Risk Factor in the Development/Severity of Acute Alcoholic Hepatitis. ( 30766965 )
2019
15
The future of therapy for alcoholic hepatitis - Beyond corticosteroids. ( 30791978 )
2019
16
Liver Transplantation for Alcoholic Hepatitis is Likely Underestimated in the National Transplant Database. ( 30882995 )
2019
17
Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis. ( 30891779 )
2019
18
A Lille Model for Predicting the Response of Severe Alcoholic Hepatitis to Corticosteroid Treatment in Japanese Patients. ( 30901152 )
2019
19
Coexistence of localized tracheobronchial amyloidosis and chronic hepatitis B infection. ( 30688286 )
2019
20
Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )
2019
21
Immunogenicity and side-effects of the inactivated hepatitis A vaccine in periodic fever, aphthous stomatitis, pharyngitis, and adenitis patients. ( 30734430 )
2019
22
Hepatitis-associated Aplastic Anemia: A Report of 3 Cases Associated With HAV. ( 29697580 )
2019
23
Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis. ( 30729702 )
2019
24
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. ( 30733983 )
2019
25
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis. ( 30630365 )
2019
26
Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. ( 30606739 )
2019
27
Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. ( 30418119 )
2019
28
Reply to: Vaccination for hepatitis B virus in an Australian pre-biologic population with rheumatoid arthritis. ( 30418127 )
2019
29
A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis. ( 30650311 )
2019
30
Autoimmune hepatitis and complexities in management. ( 30651962 )
2019
31
Editorial: the role of vitamin D in autoimmune hepatitis. ( 30663100 )
2019
32
Editorial: the role of vitamin D in autoimmune hepatitis-authors' reply. ( 30663106 )
2019
33
Tryptophan-kynurenine profile in pediatric autoimmune hepatitis. ( 30666511 )
2019
34
Review article: stopping immunosuppressive treatment in autoimmune hepatitis (AIH): is it justified (and in whom and when)? ( 30667576 )
2019
35
Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. ( 30671977 )
2019
36
Adequacy of scoring systems in diagnosing paediatric autoimmune hepatitis: retrospective study using a control group children with Hepatitis B infection. ( 30703247 )
2019
37
Autoimmune hepatitis: current and future therapeutic options. ( 30716203 )
2019
38
Steroid Free Treatment of Autoimmune Hepatitis in Selected Children. ( 30723013 )
2019
39
Risk of autoimmune hepatitis reactivation in patients with chronic hepatitis C and autoimmune hepatitis treated with direct-acting antivirals. ( 30758316 )
2019
40
Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. ( 30761563 )
2019
41
Depression: An Overlooked Villain in Autoimmune Hepatitis? ( 30773711 )
2019
42
Racial Disparities in Presentation and Outcomes of Pediatric Autoimmune Hepatitis. ( 30802337 )
2019
43
What is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? ( 30807845 )
2019
44
Long-term Clinical Outcomes in Patients with Autoimmune Hepatitis according to Treatment Response in Asian country. ( 30821090 )
2019
45
Focal Nodular Hyperplasia Mimicked Hepatocellular Carcinoma in an Autoimmune Hepatitis Patient With Regression of Cirrhosis. ( 30845888 )
2019
46
Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. ( 30850346 )
2019
47
Adoptive transfer of regulatory T cells stimulated by Allogeneic Hepatic Stellate Cells mitigates liver injury in mice with concanavalin A-induced autoimmune hepatitis. ( 30853178 )
2019
48
Secondary Hemophagocytic Lymphohistiocytosis: A Challenging Diagnosis in a Patient with Autoimmune Hepatitis. ( 30863647 )
2019
49
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? ( 30868627 )
2019
50
Letter: severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis-offender or bystander? Authors' reply. ( 30868634 )
2019

Variations for Hepatitis

ClinVar genetic disease variations for Hepatitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh37 Chromosome MT, 3275: 3275
2 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 GRCh38 Chromosome MT, 3275: 3275

Copy number variations for Hepatitis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 226111 7 55054218 55242525 Amplification EGFR Hepatitis

Expression for Hepatitis

Search GEO for disease gene expression data for Hepatitis.

Pathways for Hepatitis

Pathways related to Hepatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.74 IFNA1 IFNA2 IFNAR2
2 10.54 LMBRD1 SCARB1
3
Show member pathways
10.32 IFNA2 IFNAR2

GO Terms for Hepatitis

Biological processes related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 defense response to virus GO:0051607 9.46 IFNA1 IFNA2 IFNAR2 IFNL4
2 T cell activation involved in immune response GO:0002286 9.43 IFNA1 IFNA2
3 type I interferon signaling pathway GO:0060337 9.43 IFNA1 IFNA2 IFNAR2
4 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.4 IFNA1 IFNA2
5 natural killer cell activation involved in immune response GO:0002323 9.37 IFNA1 IFNA2
6 hepatocyte apoptotic process GO:0097284 9.32 KRT18 KRT8
7 viral entry into host cell GO:0046718 9.26 CLDN1 HAVCR1 SCARB1 SLC10A1
8 viral process GO:0016032 9.17 CLDN1 HAVCR1 KRT18 KRT8 LMBRD1 SCARB1

Molecular functions related to Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 type I interferon receptor binding GO:0005132 8.96 IFNA1 IFNA2
3 virus receptor activity GO:0001618 8.92 CLDN1 HAVCR1 SCARB1 SLC10A1

Sources for Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....